

Reactions with Dimethylformamide-Dimethylacetal: Synthesis and Reactions of Several New Pyridine and Pyrazolo[3,4-*b*]pyridine Derivatives

Mohamed A. A. Elneairy,¹ Mohamed A. M. Gad-Elkareem,² and Adel M. Taha¹

¹Department of Chemistry, Faculty of Science, Cairo University, Giza, A. R. Egypt

²Department of Chemistry, Faculty of Science, Al-Azhar University (Assiut Branch), Assiut 71524, A. R. Egypt

Received 15 December 2005; revised 12 March 2006

ABSTRACT: 6-Aminopyridine-2(1*H*)-thiones **1a,b** reacted with dimethylformamide-dimethylacetal (DMF-DMA) to give the corresponding 6-[(*N,N*-dimethylamino)methylene]amino}pyridine derivatives **2a,b**. The latter compounds reacted with hydrazine hydrate to afford the 3,6-diamino-1*H*-pyrazolo[3,4-*b*]pyridine derivative **4** and 3-amino-5-hydrazino-1*H*-pyrazolo[4',3':5,6]pyrido[2,3-*d*]pyrimidine derivative **7**, respectively. Compound **4** condensed with DMF-DMA to yield the 3,6-bis{[(*N,N*-dimethylamino)methylene]amino}-1*H*-pyrazolo[3,4-*b*]pyridine derivative **10**, which reacted with malononitrile to give the corresponding pyridopyrazolopyrimidine derivative **15**. © 2007 Wiley Periodicals, Inc. *Heteroatom Chem* 18:399–404, 2007; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hc.20312

INTRODUCTION

Synthesis and characterization of pyridines and pyrazolo[3,4-*b*]pyridines became the main target of

this research group. Several publications demonstrated this research effort [1–9]. This is because these derivatives possess diverse biological activities and are widely used in pharmaceutical and medicinal preparations. The pyridine ring found in acetylcholine, enhancement useful in the treatment of Alzheimer disease [10], and has antitumor [11], anti-amnesic [12], and antimicrobial [7] activities. Moreover, pyridine-3-carbonitriles were used as cardiogenic [13,14] and antiviral [15] agents, and pyridine-3,5-dicarbonitriles were reported to have antiproliferative activity on human cancer cell lines [16]. On the other hand, pyrazolo[3,4-*b*]pyridines were used as antimicrobials [5,7,17], inhibitors of cyclin-dependent kinases [18], antimalarial [19], and antiproliferative [20]. The above findings stimulated the interest for the synthesis of additional new numbers of these derivatives that are required in medicinal chemistry programs.

RESULTS AND DISCUSSION

It has been found that 6-amino-4-(4-methoxyphenyl)-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitrile (**1a**) [21] reacted with dimethylformamide-dimethylacetal (DMF-DMA) in dry xylene to afford a reaction product of molecular

Correspondence to: Mohamed A. M. Gad-Elkareem; e-mail: m65gad@yahoo.com.
© 2007 Wiley Periodicals, Inc.

formula $C_{17}H_{15}N_5OS$ corresponding to equimolecular addition of **1a** to the reagent followed by loss of two molecules of methanol. The IR spectrum of this reaction product showed the absence of the band of the amino group. The newly introduced *N,N*-dimethylaminomethylene group was detected in the 1H NMR spectrum of the reaction product as a singlet signal at $\delta = 3.17$ (two CH_3) and 8.91 ($N=CH$) ppm. Based on the above data, together with the data of elemental analysis, this reaction product could be formulated as 6-[[*N,N*-dimethylamino)methylene]amino}-4-(4-methoxyphenyl)-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitrile (**2a**).

Analogously, 6-amino-4-(2-furyl)-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitrile (**1b**) [22] reacted with the same reagent to give the corresponding 6-[[*N,N*-dimethylamino)methylene]amino}-4-(2-furyl)-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitrile (**2b**), whose structure was established on the basis of elemental and spectral backgrounds as previously reported for **2a** (cf. Scheme 1 and the Experimental section).

The synthetic potential of each of **2a,b** was demonstrated via their reaction with hydrazine hydrate under reflux to give different reaction products. The product of the reaction of **2a** with hydrazine hydrate showed among its signals those of two amino, one imino ($3451, 3339, 3216, 3153\text{ cm}^{-1}$), and one nitrile (2200 cm^{-1}) functions in its IR spectrum. Its 1H NMR spectrum revealed the presence of D_2O exchangeable two NH_2 ($\delta = 4.35, 6.75\text{ ppm}$) and one NH ($\delta = 11.86\text{ ppm}$) groups. This reaction product could then be formulated as the 3,6-diamino-1*H*-pyrazolo[3,4-*b*]pyridine derivative **4**.

On the contrary, the IR spectrum of the product of the reaction of **2b** with hydrazine hydrate showed the complete disappearance of the absorption bands of the nitrile functions. Instead new absorption bands of two NH_2 and two NH groups were detected. The signals of the NH_2 and NH protons ($\delta = 4.99, 6.68, 7.55, \text{ and } 11.69\text{ ppm}$) were D_2O exchanged in the 1H NMR spectrum, which also revealed the signal of 7*H*-pyrimidine at $\delta = 8.85\text{ ppm}$. Based on the above data this reaction product could be formulated as the 3-amino-5-hydrazino-1*H*-pyrazolo[4',3':5,6]pyrido[2,3-*d*]pyrimidine derivative **7** (cf. Scheme 1 and the Experimental section).


An unequivocal support for the structure of each of **4** and **7** was achieved via their synthesis through other routes as follows:

(a) Compounds **1a,b** were reacted each with one molecule of methyl iodide in DMF/potassium hydroxide solution to give the correspond-

ing 6-amino-4-aryl-2-methylthiopyridine-3,5-dicarbonitriles **8a,b**, which in turn reacted with one molecule of DMF-DMA to give the corresponding 6-[[*N,N*-dimethylamino)methylene]amino}-4-aryl-2-methylthiopyridine-3,5-dicarbonitriles **9a,b**. The structure of each of **8a,b** and **9a,b** was established on the basis of elemental analysis, and IR and 1H NMR spectral data studies (cf. the Experimental section).

- (b) Compound **4** could be prepared directly by reacting **8a** with boiling hydrazine hydrate.
- (c) Compound **9a** reacted with boiling hydrazine hydrate to give directly compound **4** with the same analytical and spectral data as those of **4** obtained by the other two methods described before. The formation of **4** in this reaction is assumed to proceed via the first formation of the nonisolable hydrazino derivative **3a** which could then be cyclized via addition to the nitrile function at position 3 and *N,N*-dimethylaminomethylene exchange of the hydrazino at position 6 under the applied reaction conditions leading to regeneration of the amino group [23] at that position and hence formation of **4** (cf. Scheme 1).
- (d) Compound **9b** reacted also with boiling hydrazine hydrate to give directly compound **7** with the same analytical and spectral data as those of **7** obtained by the other method described before. The formation of **7** in this reaction is assumed to proceed via the first formation of the nonisolable hydrazino derivative **3b** that undergoes two cyclization steps which are both addition to the nitrile functions at positions 3 and 5 leading to the formation of the corresponding nonisolable 6-amino-5-iminopyrazolo[4',3':5,6]pyrido[2,3-*d*]pyrimidine derivative **5**. Compound **5** could then lose one molecule of dimethylamine to give the nonisolable intermediate **6**. Compound **6** underwent Dimroth rearrangement [24] to give the corresponding final isolable product 3-amino-5-hydrazinopyrazolo[4',3':5,6]pyrido[2,3-*d*]pyrimidine derivative **7** (cf. Scheme 1).

Several interesting reactions took place starting from the diamino-pyrazolopyridine derivative **4**. Thus, it has been found that **4** reacted with two molecules of DMF-DMA in boiling dry xylene to give a reaction product of molecular formula $C_{20}H_{22}N_8O$ corresponding to the addition of two molecules of the reagent to one molecule of **4** followed by the loss of four molecules of methanol. The IR spectrum of this reaction product



SCHEME 2

exchange reaction [23] to give back the original compound **4** with almost the same analytical, physical (mp and mixed mp), and spectral data as for **4** previously reported (cf. Scheme 2 and the Experimental section).

EXPERIMENTAL

Melting points were measured with a Gallenkamp apparatus and are uncorrected. IR spectra in KBr discs were recorded on a Bruker Vector 22 FT-IR spectrophotometer. ¹H NMR spectra were determined in DMSO-*d*₆ and CDCl₃ at 300 MHz on a Varian Mercury VX spectrometer using TMS as an internal standard. Chemical shifts are expressed as δ ppm and *J* as Hz units. Elemental analyses were carried out at the Microanalytical Center of Cairo University. Compounds **1a** [21] and **1b** [22] were prepared according to the literature procedures.

In all the ¹H NMR spectra* = Lost after D₂O exchange.

Reactions with DMF-DMA in Dry Xylene: General Procedure

To a solution of the appropriate **1a,b**, **8a,b** (0.01 mol) or **4** (0.02 mol) in dry xylene (30 mL), DMF-DMA (0.012 mol or 0.024 mol) was added and the reaction mixture was then heated under reflux for 3–5 h. The solid so obtained after cooling was collected by filtration and crystallized from the proper solvent to yield **2a,b**, **9a,b**, or **10**, respectively.

6- $\{[(N,N\text{-Dimethylamino})\text{methylene}]\text{amino}\}$ -4-(4-methoxyphenyl)-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitrile (**2a**). Yellow crystals from dioxan (63%), mp 280–282°C; IR (cm⁻¹) ν 3148 (NH), 2221, 2209 (two CN), 1624 (N=C); ¹H NMR (DMSO-*d*₆) δ 3.17 (s, 6H, N(CH₃)₂), 3.86 (s, 3H, OCH₃), 7.11–7.55 (m, 5H, NH* & Ar-H), 8.91 (s, 1H, N=CH). Anal. For C₁₇H₁₅N₅OS (337) Calcd: C, 60.52; H, 4.48; N, 20.76; S, 9.50. Found: C, 60.80; H, 4.80; N, 21.00; S, 9.20%.

6- $\{[(N,N\text{-Dimethylamino})\text{methylene}]\text{amino}\}$ -4-(2-furyl)-2-thioxo-1,2-dihydropyridine-3,5-dicarbonitrile (**2b**). Brown crystals from dioxan (58%), mp 180°C; IR (cm⁻¹) ν 3145 (NH), 2212 (CN), 1625 (N=C). Anal. For C₁₄H₁₁N₅OS (297) Calcd: C, 53.79; H, 3.47; N, 28.95; S, 5.52. Found: C, 54.00; H, 3.70; N, 28.70; S, 5.30%.

6- $\{[(N,N\text{-Dimethylamino})\text{methylene}]\text{amino}\}$ -4-(4-methoxyphenyl)-2-methylthiopyridine-3,5-dicarbonitrile (**9a**). Yellow crystals from DMF (67%), mp 305–306°C; IR (cm⁻¹) ν 2209 (CN), 1625 (N=C). Anal. For C₁₈H₁₇N₅OS (351) Calcd: C, 61.52; H, 4.88; N, 19.93; S, 9.12. Found: C, 61.80; H, 4.50; N, 20.20; S, 8.80%.

6- $\{[(N,N\text{-Dimethylamino})\text{methylene}]\text{amino}\}$ -4-(2-furyl)-2-methylthio-pyridine-3,5-dicarbonitrile (**9b**). Pale yellow crystals from dioxan (63%), mp 230–231°C; IR (cm⁻¹) ν 2212 (CN), 1625 (N=C); ¹H NMR (CDCl₃) δ 2.60 (s, 3H, CH₃), 3.27 (s, 6H, N(CH₃)₂), 6.64 (2d, 1H, 4H-furyl), 7.56 (d, J = 3.6 Hz, 1H, 3H-furyl), 7.72 (d, J = 2.0 Hz, 1H, 5H-furyl), 8.77 (s, 1H, N=CH). Anal. For C₁₅H₁₃N₅OS (311) Calcd: C, 57.86; H, 4.88; N, 22.49; S, 10.30. Found: C, 58.20; H, 4.50; N, 22.20; S, 10.00%.

3,6-Bis $\{[(N,N\text{-Dimethylamino})\text{methylene}]\text{amino}\}$ -4-(4-methoxy-phenyl)-1H-pyrazolo[3,4-*b*]pyridine-5-carbonitrile (**10**). Orange crystals from dioxan (58%), mp 300–302°C; IR (cm⁻¹) ν 3185 (NH), 2215 (CN), 1625 (N=C); ¹H NMR (DMSO-*d*₆) δ 3.09 (s, 6H, N(CH₃)₂), 3.18 (s, 6H, N(CH₃)₂), 3.84 (s, 3H, OCH₃), 7.14 (d, J = 8.0 Hz, 2H, Ar-H), 7.46 (d, J = 8.0 Hz, 2H, Ar-H), 8.59 (s, 2H, two N=CH), 12.14 (s, 1H, NH*). Anal. For C₂₀H₂₂N₈O (390) Calcd: C, 61.52; H, 5.68; N, 28.70. Found: C, 61.80; H, 5.30; N, 28.50%.

Reaction of **1a,b** with Methyl iodide

A solution of the appropriate **1a,b** (0.01 mol) in DMF (20 mL) containing 0.01 mol of KOH was treated with methyl iodide (0.01 mol). The reaction mixtures were stirred at room temperature for 2 h, poured onto ice-cold water, and neutralized with dilute HCl (10%). The precipitates that formed were collected by filtration and crystallized from ethanol to yield **8a,b**, respectively.

6-Amino-4-(4-methoxyphenyl)-2-methylthiopyridine-3,5-dicarbonitrile (**8a**). White crystals from ethanol (78%), mp 230–232°C; IR (cm⁻¹) ν 3468, 3363 (NH₂), 2212 (CN), 1614 (N=C); ¹H NMR (DMSO-*d*₆) δ 2.71 (s, 3H, SCH₃), 3.86 (s, 3H, OCH₃), 5.30 (s, 2H, NH₂*), 7.16 (d, J = 8.0 Hz, 2H,

Ar-H), 7.45 (d, J = 8.0 Hz, 2H, Ar-H). Anal. For C₁₅H₁₂N₄OS (296) Calcd: C, 60.79; H, 4.08; N, 18.91; S, 10.82. Found: C, 61.00; H, 4.30; N, 18.60; S, 11.00%.

6-Amino-4-(2-furyl)-2-methylthiopyridine-3,5-dicarbonitrile (**8b**). Brown crystals from ethanol (75%), mp 215°C; IR (cm⁻¹) ν 3388, 3305 (NH₂), 2216 (CN), 1617 (N=C). Anal. For C₁₂H₈N₄OS (256) Calcd: C, 56.24; H, 3.15; N, 21.86; S, 12.51. Found: C, 56.60; H, 3.50; N, 21.60; S, 12.70%.

Reactions with Hydrazine Hydrate: General Procedure

A solution of the appropriate **2a,b**, **8a**, or **9a,b** (0.01 mol) in hydrazine hydrate (20 mL) was heated under reflux for 6 h and then cooled. The solid so obtained was collected by filtration and crystallized from the proper solvent to yield **4** or **7**, respectively.

3,6-Diamino-4-(4-methoxyphenyl)-1H-pyrazolo[3,4-*b*]pyridine-5-carbonitrile (**4**). Orange crystals from ethanol (65%), mp 320–322°C; IR (cm⁻¹) ν 3451, 3339, 3216, 3153 (two NH₂, NH), 2200 (CN), 1610 (N=C); ¹H NMR (DMSO-*d*₆) δ 3.87 (s, 3H, OCH₃), 4.35 (s, 2H, NH₂*), 6.75 (s, 2H, NH₂*) 7.13 (d, J = 8.0 Hz, 2H, Ar-H), 7.45 (d, J = 8.0 Hz, 2H, Ar-H), 11.86 (s, 1H, NH*). Anal. For C₁₄H₁₂N₆O (280) Calcd: C, 59.99; H, 4.32; N, 29.98. Found: C, 59.60; H, 4.60; N, 30.20%.

3-Amino-4-(2-furyl)-5-hydrazino-1H-pyrazolo[4',3':5,6]pyrido[2,3-*d*]pyrimidine (**7**). Pale yellow crystals from DMF (66%), mp >350°C; IR (cm⁻¹) ν 3419, 3324, 3218, 3122 (two NH₂, two NH), 1634 (N=C); ¹H NMR (DMSO-*d*₆) δ 4.99 (s, 2H, NH₂*), 6.68 (s, 2H, NH₂*) 6.90–7.50 (m, 3H, furyl), 7.55 (s, 1H, NH*), 8.85 (s, 1H, 2H-pyrimidine), 11.59 (s, 1H, NH*). Anal. For C₁₂H₁₀N₈O (282) Calcd: C, 51.06; H, 3.57; N, 39.70. Found: C, 51.30; H, 3.30; N, 40.00%.

Reaction of **10** with **11a,b**

A solution of **10** (0.01 mol) in glacial acetic acid (20 mL) was treated with **11a,b** (0.02 mol). The reaction mixture was heated under reflux for 4 h and then cooled. The solid products obtained were collected by filtration and crystallized from the proper solvent to yield **15** and **4**, respectively.

4,8-Diamino-10-(4-methoxyphenyl)pyrido[2',3':3,4]pyrazolo[1,5-*a*]pyrimidine-3,9-dicarbonitrile (**15**). Orange crystals from AcOH (57%), mp 260–261°C; IR (cm⁻¹) ν 3442, 3351, 3211 (two NH₂),

2213 (CN), 1610 (N=C); ^1H NMR (DMSO- d_6) δ 3.88 (s, 3H, OCH_3), 4.74 (s, 2H, NH_2^*), 6.77 (s, 2H, NH_2^*) 7.13 (d, $J = 8.0$ Hz, 2H, Ar-H), 7.50 (d, $J = 8.0$ Hz, 2H, Ar-H), 8.40 (s, 1H, 2H-pyrimidine). Anal. For $\text{C}_{18}\text{H}_{12}\text{N}_8\text{O}$ (356) Calcd: C, 60.67; H, 3.39; N, 31.45. Found: C, 60.40; H, 3.60; N, 31.20%.

REFERENCES

- [1] Attaby, F. A.; Eldin, S. M.; Elneairy, M. A. A. *Heteroat Chem* 1998, 9(6), 571.
- [2] Gad-Elkareem, M. A. M.; Abdel-Fattah, A. M.; Elneairy, M. A. A. *Phosphorus, Sulfur and Silicon* 2006, 181(4), 891.
- [3] Elneairy, M. A. A.; Gad-Elkareem, M. A. M.; Taha, A. M. J. *Sulfur Chem* 2005, 26(4-5), 381.
- [4] Gad-Elkareem, M. A. M.; Abedelhamid, A. O. *Afinidad* 2004, 61(513), 427.
- [5] Elneairy, M. A. A.; Attaby, F. A.; Elsayed, M. S. *Phosphorus, Sulfur and Silicon* 2000, 167, 161.
- [6] Elneairy, M. A. A. *Phosphorus, Sulfur and Silicon* 2003, 178, 2201.
- [7] Attaby, F. A.; Elneairy, M. A. A.; Elsayed, M. S. *Arch Pharm Res* 1999, 22(2), 194.
- [8] Elneairy, M. A. A.; Gad-Elkareem, M. A. M.; Abdel-Fattah, A. M. *Phosphorus, Sulfur and Silicon* 2006, 181(6), 1451.
- [9] Attaby, F. A.; Eldin, S. M.; Elneairy, M. A. A. *J Chem Res (S)*, 1998, 10, 632.
- [10] Andreani, A.; Leani, A.; Ville, G. *Eur J Med Chem* 2000, 35, 77.
- [11] Fujita, T.; Wada, K.; Oguchi, M.; Kurakata, S. *PCT Int Appl WO* 2001, 01 05,780; C.A. 2001, 134, 131426b.
- [12] Ammar, Y. A.; Ghorab, M. M.; El-Sharief, A. M. Sh.; Mohamed Sh. I. *Heteroat Chem* 2002, 13, 199.
- [13] Bekhit, A. A.; Baraka, A. M. *Eur J Med Chem* 2005, 40, 1405.
- [14] Krauze, A.; Vitolija, R.; Garaliene, V.; Stile, L.; Kluša, V.; Duburs, G. *Eur J Med Chem* 2005, 40, 1163.
- [15] Attaby, F. A.; Ali, M. A.; Elghandour, A. H. H.; Ibrahim, Y. M. *Phosphorus, Sulfur and Silicon* 2006, 181(1), 1.
- [16] Cocco, M. T.; Congiu, C.; Lilliu, V.; Onnis, V. *Eur J Med Chem* 2005, 40, 1365.
- [17] Goda, F. E.; Abdel-Aziz, A. A. M.; Attef, O. A. *Bioorg Med Chem* 2004, 12, 1845.
- [18] Misra, R. N.; Rawlins, D. B.; Xiao, H. Y.; Shan, W.; Bwsuker, I.; Kellar, K. A.; Mulheron, J. G.; Sack, J. S.; Tokarski, J. S.; Kimball, S. D.; Webster, K. R. *Bioorg Med Chem Lett* 2003, 13, 1133.
- [19] Menezes, C. M. S.; Sant'Anna, C. M. R.; Rodrigues, C. R.; Barreiro, E. J. J. *Mol Struct (Therochem)* 2002, 579, 31.
- [20] Poreba, K.; Oplski, A.; Wietrzyk, J. *Acta Pol Pharm* 2002, 59(3), 215.
- [21] El-Torgoman, A. M.; El-Kousy, S. M.; Kandeel, Z. E. *Z Naturforsch* 1987, 42b(1), 107.
- [22] Sharanin, Yu. A.; Krivokolysko, S. G.; Dyachenko, V. D. *Zh Org Khim* 1994, 30(4), 581; C.A., 1995, 122, 187341q.
- [23] Markarov, V. A.; Ryabova, O. B.; Alekseeva, L. M.; Shashkov, A. S.; Granik, V. G. *Chem Heterocycl Compd* 2003, 39(2), 238.
- [24] Oganisyan, A. S.; Noravryan, A. S.; Grigoryan, M. *Zh. Chem Heterocycl Compd* 2004, 40(1), 75.